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Abstract
Background: To determine the impact of AA supplementation during resistance training on body
composition, training adaptations, and markers of muscle hypertrophy in resistance-trained males.
Methods: In a randomized and double blind manner, 31 resistance-trained male subjects (22.1 ±
5.0 years, 180 ± 0.1 cm, 86.1 ± 13.0 kg, 18.1 ± 6.4% body fat) ingested either a placebo (PLA: 1
g·day-1 corn oil, n = 16) or AA (AA: 1 g·day-1 AA, n = 15) while participating in a standardized 4
day·week-1 resistance training regimen. Fasting blood samples, body composition, bench press one-
repetition maximum (1RM), leg press 1RM and Wingate anaerobic capacity sprint tests were
completed after 0, 25, and 50 days of supplementation. Percutaneous muscle biopsies were taken
from the vastus lateralis on days 0 and 50.
Results: Wingate relative peak power was significantly greater after 50 days of supplementation
while the inflammatory cytokine IL-6 was significantly lower after 25 days of supplementation in the
AA group. PGE2 levels tended to be greater in the AA group. However, no statistically significant
differences were observed between groups in body composition, strength, anabolic and catabolic
hormones, or markers of muscle hypertrophy (i.e. total protein content or MHC type I, IIa, and IIx
protein content) and other intramuscular markers (i.e. FP and EP3 receptor density or MHC type
I, IIa, and IIx mRNA expression).
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Conclusion: AA supplementation during resistance-training may enhance anaerobic capacity and
lessen the inflammatory response to training. However, AA supplementation did not promote
statistically greater gains in strength, muscle mass, or influence markers of muscle hypertrophy.
Background
Nutritional supplements are often marketed to resistance-
trained athletes as nutritional ergogenic aids purported to
promote gains in strength, muscle mass, and/or perform-
ance during training. For example, creatine, amino acids
(i.e., branched chain amino acids, arginine, etc.), polyun-
saturated fatty acids (i.e., fish oils), dihydroepiandroster-
one (DHEA), and antioxidants (i.e. vitamin E, catechins,
etc.) have been shown to exhibit anabolic, anti-catabolic,
and/or ergogenic properties in young, healthy [1] and dis-
eased populations [2-6]. Consequently, although equivo-
cal data exists [7,8], supplements have also been marketed
as ergogenic aids for athletes. Moreover, new nutrients are
continually introduced as potential nutritional ergogenic
aids for this population. While there is some basic and/or
applied data available to support the potential ergogenic
value of some nutritional supplements, many lack data
supporting efficacy and/or safety [9].
A nutrient that has recently been purported to possess
anabolic properties and marketed to resistance-trained
athletes is arachidonic acid (AA). Arachidonic acid (20:4,
ω-6) is a polyunsaturated fatty acid that is consumed in
low amounts in the diet and is relatively abundant in
membrane phospholipids. The fatty acid content in sarco-
plasmic membrane phospholipids is thought to be con-
tingent upon dietary habits [10,11] and physical activity
levels [12,13]. Consequently, a high dietary intake of ω-6
fatty acids increases the endogenous ω-6 fatty acid content
of membrane phospholipids, while active individuals
present a lower ω-6-to-ω-3 ratio compared to their seden-
tary counterparts, respectively. Furthermore, AA has been
reported to be a bioactive compound involved in myo-
genic inflammation processes that occurs in response to
mechanical strain such as resistance-training [14,15]. In
this regard, products of AA metabolism include explicit
prostaglandin isomers (i.e., PGE2, PGF2α), which are
formed through the cyclooxygenase-2 isozyme (COX-2)
pathway. Recent studies examining the inhibition of the
COX-2 pathway have discerned that COX-2 isozyme
products mitigate protein degradation and subsequent
myofibrillar regeneration in skeletal muscle [16,17]. A
recent investigation by Trappe et al. [18] demonstrated
that when males supplemented with COX-2 inhibitors
(i.e., ibuprofen and acetaminophen) prior to resistance
training, post-exercise PGF2α production and muscle pro-
tein synthesis was completely abolished following an
eccentric resistance training protocol. Trappe and col-
leagues concluded that COX-2 inhibition inhibited post-
exercise protein synthesis due to the cessation of PGF2α
formation [18]. In addition, previous research suggests
that 1.5 g·d-1 of AA supplementation for 50 d in young,
healthy men significantly increased leukocytic prostaglan-
din production [19], although, no measures of protein
synthesis were made in this study.
Therefore, it is plausible that AA levels are lower in resist-
ance-trained individuals due to their elevated activity lev-
els, and that supplementation may increase intramuscular
AA pools during resistance training. Due to the fact that
AA is a substrate of the COX-2 isozyme that is converted
into PGF2α, potentially increasing intracellular AA via
nutritional supplementation may potentiate the post-
exercise production of PGF2α. Furthermore, possible post-
exercise increases in PGF2α with AA supplementation may
further enhance muscle protein synthesis and lead to sub-
sequent muscle hypertrophy over chronic supplementa-
tion periods with concurrent resistance training. However,
we are aware of no research that has examined the effects
that AA supplementation on circulating prostaglandins
and/or skeletal muscle mass and function. Therefore, the
purpose of this study was to investigate whether AA sup-
plementation in conjunction with resistance training
affects body composition, training adaptations, and hor-
monal and cellular markers of muscle hypertrophy and
inflammation in resistance-trained individuals.
Methods
Subjects
Thirty-one healthy, resistance trained males (22.1 ± 5.0
yrs, 180 ± 0.1 cm, 86.1 ± 13.0 kg, 18.1 ± 6.4% body fat)
were informed of study protocol approved by the Institu-
tional Review Board at Baylor University prior to partici-
pation. Training status was self-reported, and individuals
who lacked at least one year of experience prior to study
were excluded. In addition, subjects were excluded if they:
1) had any history of metabolic, hypertension, hepatore-
nal, musculoskeletal, autoimmune, or neurologic disease;
2) were currently taking thyroid, antihyperlipidemic,
hypoglycemic, anti-hypertensive, or androgenic medica-
tions; and 3) had taken nutritional supplements that may
affect muscle mass [i.e., creatine, hydroxy-beta-methylbu-
tyrate (HMB)] and/or anabolic/catabolic hormone levels
[i.e. androstenedione, dihydroepiandrosterone (DHEA),
or other prohormones] within three months of the start-
ing the study.Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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Baseline testing
Eligible subjects were familiarized to the study protocol
via a verbal and written explanation of the study design.
Subjects signed an informed consent statement and com-
pleted personal and medical histories while also complet-
ing a Wingate anaerobic capacity test prior to baseline
testing. Subjects were instructed to refrain from strenuous
exercise for 48 hours and fast for 10 hours prior to base-
line testing (i.e., day 0) which occurred 3–4 days follow-
ing familiarization to allow for recording of dietary
intake. This study employed a double-blind, placebo-con-
trolled, parallel study design whereby subjects were
matched evenly into clusters according to age and body
mass.
Experimental protocol
During days 0, 25, and 50 each subject reported to the lab-
oratory after a 10-hour fast. Height was measured using
standard anthropometry and total body mass was meas-
ured using a calibrated Healthometer digital strain gauge
electronic scale (Bridgeview, IL) with a precision of ± 0.02
kg. Body composition was then determined using a cali-
brated Hologic Discovery W dual-energy x-ray absorpti-
ometer (DXA) device (Hologic Inc., Bedford, MA), while
blood pressure and resting heart rate was determined
using standard procedures. Subjects then donated approx-
imately 25 ml of fasting blood using standard venipunc-
ture techniques for hematological, clinical chemistry
panels and later cytokine and hormone analysis. Two 10
ml serum separation vacutainer tubes and one 5 ml K3
EDTA vacutainer tube were inserted into the vacutainer
holder for blood collection in succession using multiple
sample phlebotomy techniques. Whole blood was imme-
diately analyzed for a complete blood count while serum
vacutainer tubes were centrifuged at room temperature for
15 min at 1,500 g, the serum supernatant was transferred
into microcentrifuge tubes, and the serum samples were
stored at -20°C for subsequent hormonal and metabolite
analyses. On days 0 and 50 only, subjects donated approx-
imately 60 mg of skeletal muscle from the vastus lateralis
using the Bergstrom biopsy technique. Upper and lower
body strength were assessed using standard 1RM testing
procedures [20] with a bench press and 35° hip sled
machine (Nebula, Versailles, OH). Test-retest reliability of
these strength tests on resistance-trained subjects in our
laboratory have yielded a high reliability for the bench
press (r = 0.94) and leg press (r = 0.91). After determina-
tion of hip sled 1RM, subjects rested 10 minutes before
completing a 30 seconds Wingate anaerobic capacity test
on a computerized cycle ergometer (Lode Excalibur, Lode,
Groningen, The Netherlands) to assess lower body anaer-
obic power. This test consisted of having each subject
sprint in an all out fashion on the bicycle ergometer for 30
seconds against a standard workload of 0.075 kg·kg-1 of
body weight. Test-retest reliability for absolute peak
power and mean power in our laboratory have also
yielded high reliability values (r  = 0.69 and r  = 0.95,
respectively, P < 0.05).
Percutaneous muscle biopsies
Muscle biopsies were taken on days 0 and 50 prior to all
strength testing to avoid potential myofibrillar disruption
due to exercise [21]. Subjects were instructed to refrain
from exercise 48 hours prior to each muscle biopsy. Mus-
cle was extracted from the lateral portion of the vastus lat-
eralis midway between the patella and iliac crest of the
dominant leg using a 5 mm biopsy needle with applied
suction [22]. Briefly, 1.5 ml of 1.0% Lidocaine HCl was
injected subcutaneously prior to making a small pilot
incision. Using double-chop procedures and applied suc-
tion, the specimen first had all visible fat and connective
tissue removed prior to being flash frozen in liquid nitro-
gen. All samples were subsequently stored at -80°C until
later analyses.
Supplementation protocol and dietary monitoring
In a double-blind fashion, subjects ingested four 250 mg
capsules containing a corn oil placebo or AA (X-Factor,
Molecular Nutrition, Jupiter, FL) over 50 days following
baseline testing. Supplements were prepared in capsule
form and packaged in generic bottles by Molecular Nutri-
tion. Compliance was monitored by having subjects
return empty supplement bottles after 25 and 50 days of
supplementation. In accordance with previous guidelines
and in an effort to ensure energy and protein intake were
adequate to facilitate muscle hypertrophy, all subjects
were instructed to increase caloric intake by approxi-
mately 500 kcal·day-1 while also maintaining an esti-
mated protein intake of 2 g·kg-1·day-1 when compared to
baseline dietary analysis [23]. Subjects were provided a
commercially-available meal replacement powder (Lean
Body, Labrada Nutrition, Houston, TX) containing
approximately 290 kilocalories, 24 g of carbohydrate, 45
g of protein and 1 g of fat per serving in an attempt to
accommodate the above mentioned energy and protein
requirements. Depending on baseline protein intake, sub-
jects were told to ingest 1 to 2 packets of the meal replace-
ment supplement in the morning and/or immediately
following each workout [24]. Additionally, subjects were
instructed to avoid regular consumption of foods known
to be high in ω-3 fatty acids including fish oil, flaxseed oil,
cold water fish, olive oil, sesame oil, peanut butter, N-
acetyl-cysteine, conjugated linoleic acid, as well as anti-
inflammatory medications including acetaminophen,
ibuprofen, aspirin and other non-steroidal anti-inflam-
matory drugs [18]. Dietary intake as well as linoleic (18:2,
ω-6), linolenic (18:3, ω-3), and AA intake were monitored
with 4-day dietary recalls at days 0, 25 and 50 and assessed
using the Food Processor III Nutrition Software (ESHA
Nutrition Research, Salem, OR).Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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Resistance-training protocol
Over a 50-day period, subjects completed a 4 day·week-1
split-body, linear periodization resistance-training pro-
gram. Upper body lifts included bench press, lat pull,
shoulder press, seated rows, shoulder shrugs, chest flies,
biceps curls, and triceps press-downs while lower body
lifts included leg press, back extension, step ups, leg curls,
leg extension, heel raises, and abdominal crunches twice
per week. Subjects performed 3 sets of 10 repetitions with
as much weight as they could lift per set (i.e., 60–80% of
1RM). Rest periods between exercises did not exceed 3
minutes, while the rest between sets did not exceed 2 min-
utes. Training was conducted at the university's student
life center, documented in training logs, and signed off by
designated staff members to verify compliance and moni-
tor progress. This protocol has been shown in prior
research to promote significant gains in muscular
strength, muscular endurance, and fat free mass [25].
Serum and whole blood analyses
Serum and whole blood samples were used to evaluate
clinical safety during the supplementation protocols.
Serum samples were assayed for comprehensive meta-
bolic panels including glucose, total protein, blood urea
nitrogen (BUN), creatinine, BUN/creatinine ratio, uric
acid, aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), creatine kinase (CK), lactate dehy-
drogenase (LDH), gamma-glutamyl transpeptidase
(GGT), albumin, globulin, sodium, chloride, calcium,
carbon dioxide, total bilirubin, alkaline phosphatase
(ALP), triglycerides, cholesterol, HDL and LDL using a
Dade Dimension XL clinical chemistry system (Dade
Behring Inc., Newark, DE). Complete blood cell counts
including red cell counts, hemoglobin, hematocrit, mean
cell volume, mean corpuscular hemoglobin, mean cor-
puscular hemoglobin concentration, red cell distribution
width, white blood cell counts, neutrophils, lymphocytes,
monocytes, eosinophils, and basophils were analyzed via
flow cytometry using the Cell-DYN 1800 (Abbott Labora-
tories, Abbott Park, IL). Test to test reliability (within and
between) of performing these assays ranged from 2 to 6%
for individual assays with an average coefficient of varia-
tion (CV) of 3.0%. Samples were run in duplicate to verify
results if the observed values were outside control values
and/or clinical norms according to standard procedures.
Subsequent serum samples were later assayed for cortisol
(CORT), free testosterone (fTEST), total testosterone
(tTEST), interleukin-6 (IL-6), prostaglandin E2 (PGE2) and
prostaglandin F2α (PGF2α). Commerical enzyme immu-
noabsorbent assays were used to analyze serum concen-
trations of PGF2α, PGE2, and IL-6 (Cayman Chemical,
Ann Arbor, MI) and CORT, fTEST, and tTEST (Diagnostic
Systems Laboratories, Webster, TX). The CV of performing
these EIA-based assays ranged from 3.0 to 5.0%.
Total RNA isolation
Total cellular RNA was extracted from the homogenate of
biopsy samples with a monophasic solution of phenol
and guanidine isothiocyanate contained within the TRI-
reagent (Sigma Chemical Co., St. Louis, MO) [26-30].
Total RNA concentrations from each sample were deter-
mined spectrophotometrically with an optical density of
260 nm (OD260), with final concentration adjusted to 200
ng·µl-1  by diluting the crude total RNA extracts into
DEPC-treated nuclease-free H2O. This procedure has been
shown to yield un-degraded RNA, free of DNA and pro-
teins as indicated by prominent 28S and 18S ribosomal
RNA bands, as well as an OD260/OD280 ratio of approxi-
mately 2.0 [26-30]. The RNA samples were stored at -
80°C until later analyses.
Reverse transcription and clonal DNA synthesis
The standardized solutions of total cellular RNA were
reverse transcribed to synthesize clonal DNA (cDNA) as
described previously [26-30]. In short, a reverse transcrip-
tion reaction mixture [i.e., 1 µl of total cellular RNA, 4 µl
5× reverse transcription buffer, a dNTP mixture contain-
ing dATP, dCTP, dGTP, and dTTP, MgCl2, RNase inhibi-
tor, an oligo(dT)15 primer, 10 µL of nuclease-free H2O and
1 U·µl-1 MMLV reverse transcriptase enzyme (Bio-Rad,
Hercules, CA)] were incubated at 42°C for 40 minutes,
heated to 85°C for 5 minutes, and then quick-chilled on
ice yielding the cDNA product. Starting cDNA template
concentrations were standardized to 200 ng·µl-1 prior to
real-time polymerase chain reaction (RT-PCR) amplifica-
tion by detecting crude cDNA synthesized products spec-
trophotometrically at a wavelength of 260 nm and
diluting them in nuclease-free H2O. The standardized
cDNA solutions were frozen at -80°C until real-time RT-
PCR was performed.
RT-PCR
Anti-sense and sense oligonucleotide primer pairs were
constructed using commercially available Beacon
Designer software (Bio-Rad, Hercules, CA) from known
mRNA sequences published in the GenBank nucleotide
database [31] and commercially synthesized (Integrated
DNA Technologies, Coralville, IA). The following 5' sense
and 3' anti-sense oligonucleotide primers were used to
isolate the three adult MHC isoforms (Type I, IIa, and IIx):
Type I MHC mRNA (5' primer: bases 776–796, 3' primer:
bases 1398-1378, GenEMBL AC X06976), Type IIa MHC
mRNA (5' primer: bases 1785–1805, 3' primer: bases
2440-2420, GenEMBL AC AF111784), Type IIx MHC
mRNA (5' primer: bases 1138–1158, 3' primer: bases
1746-1726, GenEMBL AC AF111785). These primers
amplify fragments of 141, 145, and 148 base pairs, respec-
tively, for Type I, IIa, IIx MHC. β-actin was used as an
external reference standard for detecting relative change in
the quantity of target mRNA due to its consideration as aJournal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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constitutively expressed housekeeping gene [32], These β-
actin primers amplify a PCR fragment of 135 base pairs.
Two hundred ng of cDNA was added to each of the four
PCR reactions for MHC Type I, -IIa, and -IIx, and β-actin.
Specifically, each PCR reaction contained the following
mixtures: 2 µl of cDNA template was added along with
12.5 µl of 2× SYBR Green Supermix (Bio-Rad, Hercules,
CA) [100 mM KCl mixture, 40 mM Tris-HCl, 0.4 mM of
each dNTP, 50 U·ml-1 of iTaq DNA polymerase, 6.0 mM
MgCl2, SYBR Green I, 20 nM flourescein], 1.5 µl of sense
and anti-sense primers and 7.5 µl nuclease-free dH2O].
Each PCR reaction was amplified with a thermal cycler
(Bio Rad, Hercules, CA) and the amplification sequence
involved a denaturation step at 95°C for 30 seconds,
primer annealing at 55°C for 30 seconds, and extension
at 72°C for 60 seconds [27,33,34]. RT-PCR was per-
formed over 40 cycles with emitted fluorescence from the
SYBR green fluorophore being measured after each cycle.
An emission of fluorescence occurs due to the integration
of the SYBR green into the double-stranded cDNA pro-
duced during the PCR reaction. All CT values were assessed
in the linear portion of amplification and a DNA melting
curve analysis was performed after amplification to assure
that the single gene products were amplified in absence of
primer-dimers. Quantification of all mRNA was expressed
relative to β-actin expression. A comparison of CT value
ratios [Day 0 (MHC mRNA CT/β-actin mRNA CT) versus
Day 50 (MHC mRNA CT/β-actin mRNA CT)] were used to
compare changes in basal gene expression between the AA
and PLA groups. Agarose gel electrophoresis using 25 µl
aliquots of the finalized PCR reaction mixtures was per-
formed in 1.5% agarose gels [1 µg·ml-1] using 1× Tris-
Boric acid-EDTA (TBE) buffer and illuminated with a UV
transilluminator (Chemi-Doc XRS, Bio-Rad, Hercules,
CA) to verify positive amplification of target mRNA (data
not shown) [33,34]. The CV for MHC I, IIa, and IIx were
2.06%, 3.18%, and 2.73%, respectively [33].
Total muscle protein quantitation
Total protein remaining from the total RNA isolation pro-
cedure was isolated with isopropanol, ethanol, and 0.3 M
guanidine hydrochloride. Myofibrillar protein was iso-
lated with 0.1% sodium dodecyl sulfate (SDS) [35], prior
to having protein content determined spectrophotometri-
cally using a Bradford assay at a wavelength of 595 nm. A
standard curve was generated using (r2 = 0.98, P < 0.001)
bovine serum albumin as the standard and represented
relative to muscle wet weight [36]. Each protein sample
was subsequently diluted to 50 µg of protein per 30 µl
SDS buffer for subsequent immunoblotting. The CV for
myofibrillar protein was 2.03% [28].
MHC protein isoform quantitation
The composition of MHC protein isoforms within each
muscle homogenate sample was determined by auto-
mated SDS-PAGE using Experion Pro260 chips (Bio-Rad,
Hercules, CA). Approximately 6 µl aliquots of each sam-
ple were pipetted into each sample well on the microchip.
Each unknown sample was prepared from 4 µl of the pro-
tein dilution from each subject (or 4 µl of the molecular
weight ladder), 2 µl of sample buffer with β-mercaptoeth-
anol, and 84 µl of de-ionized water. Based upon the find-
ings of Gazith and colleagues [37], all three MHC
isoforms were expected to migrate in the 200–210 kilo-
Daulton region within the polyacrylamide gel relative to
the molecular weight ladder. The gels were digitally visu-
alized by the Experion software (Bio-Rad, Hercules, CA)
and MHC concentrations in each sample were assessed by
comparing the arbitrary density of each MHC isoform to
the arbitrary densities of molecular weight markers with
known concentrations. The CV of protein bands ≥10 kD
were ≤1.1%.
Protein immunoblotting
PGF2α (FP) and PGE2 (EP3) receptor quantitation was per-
formed at room temperature by extracting total muscle
protein from the homogenate and slot-blotting 50 µg of
total protein onto nitrocellulose membranes using a Bio-
Dot protein blotting system (Bio-Rad, Hercules, CA). The
blotted membranes were incubated with blocking solu-
tion for 1 hour on an orbital rocker, decanted and mem-
branes were incubated with a TTBS wash solution for 5
minutes for a total of three washes. The membranes were
incubated with specific anti-FP receptor and anti-EP3
receptor polyclonal antibodies (Cayman Chemical, Ann
Arbor, MI), diluted to 4 µg·ml-1, for 1 to 2 hours on an
orbital rocker. Primary antibody solutions were then
decanted and the membranes washed with TTBS solution
for 5 minutes on an orbital rocker for a total of three
washes. The TTBS wash solution was decanted and the
membranes were incubated with a secondary biotinylated
goat anti-rabbit antibody solution (Bio-Rad, Hercules,
CA) for 1 hour on an orbital rocker. Continuing, the sec-
ondary biotinylated goat anti-rabbit antibody solution
was decanted and the membranes incubated in TTBS wash
solution for a total of three washes at 5 minutes per wash.
The membranes were incubated with a streptavidin-bioti-
nylated alkaline phosphatase complex solution (Bio-Rad,
Hercules, CA) for 1 hour on an orbital rocker. Finally, the
streptavidin-biotinylated alkaline phosphatase complex
solution was decanted and the membranes washed three
times with TTBS solution at 5 minutes per wash on an
orbital shaker. Color development solution containing
BCIP/NBT (Bio-Rad, Hercules, CA) was added and color
development was monitored over 30 – 60 minutes. The
color development was stopped by incubating the mem-
brane in double distilled H2O for 10 minutes on an
orbital rocker. Blotted membranes were digitized by way
of densitometry using a Chemi-Doc XRS imaging systemJournal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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(Bio-Rad, Hercules, CA) and band density was expressed
in integrated density units relative to muscle weight.
Statistical analysis
Statistical analyses were performed using SPSS (version
14.0, SPSS Inc., Chicago, IL). Whole blood, serum, per-
formance, and body composition variables were analyzed
using 2 × 3 (group × testing session) analysis of variance
(ANOVA) with repeated measures univariate tests. MHC
protein, FP and EP3 receptor protein levels were analyzed
using separate 2 × 2 (group × testing session) ANOVA with
repeated measures. Additionally, in the case of significant
main effect for group, one-way ANOVAs with repeated
measures on testing sessions was performed for each
group to assess any differences between tests. Independ-
ent t-tests were used to analyze the changes in MHC
mRNA expression after 50 days of supplementation. In
addition to raw score analysis, delta score analysis (i.e. day
0 values subtracted from day 25 and/or 50) was per-
formed for variables that exhibited extraneous variation
between groups on day 0. As mentioned with raw scores,
a 2 × 3 (group × testing session) analysis of variance
(ANOVA) with repeated measures univariate tests was
used to analyze delta scores for body composition, per-
formance variables, and hormone concentrations whereas
a 2 × 2 repeated measures ANOVA was used to analyze all
intramuscular delta scores. In circumstances where equal
variances within groups could not be assumed, the
Hunyhs-Feldt epsilon correction factor was used to adjust
within group F-ratios. In circumstances where statistical
trends appeared to exist (i.e., P = 0.05 to 0.10), effect sizes
were also reported as partial Eta squared (ηp
2). Partial Eta
squared effect sizes were determined to be weak (ηp
2 ≤
0.01), medium (ηp
2 = 0.06), strong = (ηp
2 = 0.14) as pre-
viously described [38]. Significance for all statistical anal-
yses was determined using an alpha level of 0.05. It
should be noted that an a priori power analysis of the
design indicated that an n-size of 15 participants per treat-
ment would yield a high power (> 0.8) for criterion varia-
ble delta values of 0.75 to 1.25. It should also be noted
that  post hoc outlier analysis using box plots was per-
formed in circumstances where there were significant
group × time interactions to ensure there were no outliers
present. All data are reported as means ± standard devia-
tions (SD).
Results
Demographics
Baseline demographics were calculated for both groups
(Table 1). No adverse side effects for any subject were
reported to the research nurse throughout the study as
both the training and supplementation regimens were
well tolerated. Dietary protein intake increased by 67.9 ±
33.4 g·day-1 in both groups which increased relative pro-
Table 1: Body Composition and Strength Changes.
Variable AA (n = 15) PLA (n = 16) Significance
Body Mass (kg)
Day 0 85.1 ± 11.5 87.1 ± 14.5 Group: 0.70
Day 25 85.6 ± 11.6 87.9 ± 14.4 Time: 0.001
Day 50 86.6 ± 12.2 88.1 ± 13.0 G × T: 0.31
FFM (kg)
Day 0 59.9 ± 8.2 63.9 ± 8.4 Group: 0.19
Day 25 60.9 ± 8.1 64.8 ± 8.2 Time: 0.001
Day 50 61.1 ± 8.5 64.9 ± 8.0 G × T: 0.71
Fat mass (kg)
Day 0 15.8 ± 5.6 13.8 ± 7.3 Group: 0.35
Day 25 15.5 ± 5.7 13.5 ± 6.9 Time: 0.24
Day 50 16.3 ± 5.9 13.8 ± 7.2 G × T: 0.22
%BF (%)
Day 0 19.9 ± 6.1 16.5 ± 6.5 Group: 0.12
Day 25 19.3 ± 6.1 15.9 ± 5.9 Time: 0.02
Day 50 20.0 ± 6.0 16.3 ± 6.2 G × T: 0.43
Bench Press 1RM (kg)
Day 0 103.0 ± 24.9 113.5 ± 24.6 Group: 0.26
Day 25 107.0 ± 23.4 118.5 ± 23.0 Time: < 0.001
Day 50 114.4 ± 25.8 121.5 ± 21.5 G × T: 0.20
Leg press 1RM (kg)
Day 0 370.8 ± 113.5 413.4 ± 80.4 Group: 0.26
Day 25 379.2 ± 109.5 416.8 ± 77.2 Time: < 0.001
Day 50 395.8 ± 123.8 436.1 ± 78.9 G × T: 0.8
Values are expressed as means ± SD.
AA: Arachidonic acid, PLA: placebo, %BF: body fat percentage, 1RM: one-repetition maximum.Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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tein intake from 1.3 ± 0.4 g·kg·day-1 (Day 0) to 2.0 ± 0.5
g·kg·day-1 (Day 50). As expected, AA intake significantly
increased in the AA group at days 25 (AA: 1.08 ± 0.12 vs.
PLA: 0.26 ± 0.50 g·day-1, P < 0.001) and 50 (AA: 1.09 ±
0.12 vs. PLA: 0.24 ± 0.47 g·day-1, P < 0.001) compared to
the PLA group. No significant group × time interactions
were found for dietary linoleic or linolenic acid intake val-
ues throughout the course of the study, although linoleic
acid intake significantly decreased from day 0 to 50 in
both groups (day 0 – day 50 = -3.29 ± 6.42 g·day-1, P =
0.03). In addition, no between-group differences in train-
ing volume were found throughout the study (AA: 4,303
± 1,291 vs. PLA: 4,105 ± 641 kg·kg bodyweight-1, P =
0.59).
Body composition and performance
Table 1 presents body composition and strength results
for the PLA and AA groups. No significant group × time
interaction changes were observed among groups in body
mass (P = 0.31), fat free mass (P = 0.71), fat mass (P =
0.22), percent body fat (P = 0.43), 1RM bench press (P =
0.20), or 1RM leg press (P = 0.84).
Table 2 presents results of the anaerobic capacity test. A
significant group × time interaction for relative Wingate
peak power was observed among groups (P = 0.02) with
gains in peak power being significantly greater in the AA
group (0.3 ± 1.2 W·kg-1) vs. PLA (0.2 ± 0.7 W·kg-1, Figure
1). Using repeated measures ANOVA with delta scores, AA
experienced significantly greater increases in comparison
to the PLA group at day 50 (P < 0.05). Statistical trends
were seen in Wingate total work (AA: 1,292 ± 1,206 vs.
PLA: 510 ± 1,249 J, P = 0.09, ηp
2 = 0.052), favoring the AA
group.
General clinical blood analyses
There was no significant group × time interactions for red
blood cell, white blood cell count, or white blood cell dif-
ferentials over the course of the study. Furthermore, no
significant group × time interactions existed for serum
triglycerides, total cholesterol, glucose, hepatic enzymes
(i.e., GGT, AST, ALT), hepatic proteins (i.e., total protein,
albumin, bilirubin), electrolytes (i.e., sodium, potassium,
chloride, calcium), crude markers of kidney integrity (i.e.,
ALP, BUN, creatinine, uric acid), or crude markers of mus-
cle damage (i.e., CK, LDH) throughout the duration of the
study.
Anabolic and catabolic hormones/cytokines
No significant group × time effect interactions were
observed tTEST (P = 0.89), fTEST (P = 0.51), and CORT (P
= 0.81) (Table 3). A statistical trend was found for serum
changes in PGE2 (AA: 98.5 ± 217 vs. PLA: -73.8 ± 273
pg·ml-1, P = 0.06, ηp
2 = 0.06). IL-6 levels experienced a
significant group × time interaction (P  = 0.04) among
groups with subsequent post-hoc analyses revealing that
IL-6 was significantly lower at day 25 of the study. One-
way ANOVA of IL-6 delta values at day 25 revealed signif-
icantly greater increases in PLA when compared to AA
group (AA: 0.8 ± 13.5 pg·ml-1 vs. PLA: 52.5 ± 1.6 pg·ml-
1, P = 0.01; Figure 2).
Intramuscular gene and protein expression
Table 4 presents muscle protein content, MHC fiber pro-
tein content, MHC mRNA expression, and FP and EP3
receptor levels observed for each group in response to
training. A significant group × time interaction (P = 0.02)
in myofibrillar protein levels was found among groups.
Post-hoc analysis revealed that the PLA group (1.6 ± 0.5
µg·g-1) demonstrated significantly greater total muscle
protein levels at day 50 in comparison to AA (0.5 ± 0.1
Table 2: Anaerobic Performance Changes.
Variable AA (n = 15) PLA (n = 16) Significance
Wingate Mean Power (W·kg-1)
Day 0 8.3 ± 1.2 8.9 ± 0.7 Group: 0.17
Day 25 8.5 ± 1.1 8.9 ± 0.8 Time: 0.35
Day 50 8.6 ± 1.2 9.1 ± 0.7 G × T: 0.08
Wingate Peak Power (W·kg-1)
Day 0 16.9 ± 3.1 18.3 ± 2.6 Group: 0.50
Day 25 17.9 ± 2.6b 18.3 ± 2.8 Time: 0.11
Day 50 18.1 ± 2.6b 18.1 ± 2.8 G × T: 0.02
Wingate Total Work (Joules)a
Day 0 21,102 ± 3,620 22,388 ± 4,222 Group: 0.18
Day 25 21,658 ± 3,307 23,340 ± 3,909 Time: 0.001
Day 50 22,394 ± 4,096 23,899 ± 3,493 G × T: 0.052
Values are expressed as means ± SD.
AA: Arachidonic acid, PLA: placebo.
aSignificant main effect over time, p < 0.01.
bSignificant within-group difference from baseline values, p < 0.05.Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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µg·g-1). No significant group × time interactions were
found in FP and EP3 receptor density values. Basal MHC
gene expression was not affected by AA supplementation
as no significant group × time interactions were observed
concerning changes in Type I, IIa, and IIx MHC protein or
mRNA levels. A significant main effect over time (P  <
0.01) for changes in MHC IIa protein levels were found in
both groups indicating that training primarily promoted
gains in MHC IIa fiber protein content. However, no sta-
tistical differences were observed between groups.
Discussion
Prior preliminary research has suggested that prostanoid
signaling may mitigate post-exercise inflammation and/or
muscle protein synthesis [18,39]. For this reason, AA sup-
plementation has been marketed as a dietary supplement
designed to promote muscle hypertrophy in resistance
trained athletes. To date, we are not aware of any study
that has been conducted to assess this theoretical role of
AA supplementation during resistance-training. There-
fore, the purpose of this study was to determine whether
AA supplementation during training affects body compo-
sition, circulating hormones, intracellular markers of
muscle hypertrophy, and/or exercise performance in expe-
rienced resistance-trained males. The major findings from
this study were that AA supplementation significantly
increased anaerobic peak power by 8.5% at day 50 (P <
0.05) and attenuated the increases in circulating IL-6 lev-
els that were seen in the PLA group (AA: 138.0 ± 83.1
pg·ml-1, PLA: 172.6 ± 90.5 pg·ml-1, P < 0.05) on day 25
of the study. Statistical trends were also found for PGE2
increases (98.5 ± 217 vs. PLA: -73.8 ± 273 pg·ml-1, P =
0.06) in the AA group. These findings suggest that AA sup-
plementation may increase prostaglandin levels in the
blood and provide a potential ergogenic value for athletes
engaged in high-intensity exercise. Additionally, that sub-
jects engaged in intense training may be able to tolerate
training with less inflammation as indicated by lower IL-
6 levels. However, no significant differences were seen
between groups in changes in body composition, circulat-
ing anabolic hormones, and/or intramuscular markers of
muscle hypertrophy. These findings do not support claims
that AA supplementation during resistance training stim-
ulates muscle hypertrophy leading to greater gains in
strength and/or muscle mass.
Changes in body composition and performance variables
Gains in strength and fat free mass for all subjects were
similar to results previously reported using this linear
periodization training program. However, AA supplemen-
tation did not induce statistically greater gains in strength
or fat free mass during training when compared to the PLA
group. Although more research is needed, these findings
do not support claims that AA supplementation during
resistance-training promotes lean tissue accretion. Inter-
estingly, AA supplementation significantly increased rela-
tive peak power during the Wingate test (P = 0.02). Post-
hoc analysis revealed that relative peak power was greater
in the AA group after 50 days when compared to the PLA
group. Statistical trends were also observed in mean
power (P = 0.08) and total work (P = 0.052) performed
during the 30-second sprint test. The Wingate anaerobic
capacity test is considered to be a valid and reliable assess-
ment of anaerobic power and capacity. Therefore, these
findings suggest that AA may enhance anaerobic capacity.
In support of this finding, recent literature suggests that 10
days of soybean-derived phosphatidylserine supplemen-
tation can significantly increase the time-to-fatigue and
total work performed in active males during an 85%
VO2max cycling bout [40]. Phosphatidylserine is a soy
bean-derived phospholipid that contains AA [41]. Kings-
ley  et al. (2006) hypothesized that phosphatidylserine
supplementation may increase exercise capacity by delay-
ing fatigue and sustaining intracellular calcium levels
through an increase in the density of Ca2+ ATPase pumps
in the sarcoplasmic reticulum of skeletal muscle [40]. Col-
lectively, these findings provide preliminary framework
that AA may have been responsible for the significant
increase in Wingate peak power. However, neither our lab
nor Kingsley's group quantified acute changes in intra-
muscular calcium during exercise. Hence, further research
is needed to examine the role of AA on intramuscular cal-
Delta changes in Wingate peak power normalized to body  mass over the 50 d supplement intervention Figure 1
Delta changes in Wingate peak power normalized to body 
mass over the 50 d supplement intervention. All values are 
expressed as means ± SD. ‡Significantly different from base-
line, p < 0.05. †Significant group × time interaction between 
AA and PLA groups, p < 0.05. AA: Arachidonic acid (n = 15); 
PLA: placebo (n = 16).Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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cium and anaerobic exercise capacity before these conclu-
sions can be drawn.
Hormonal adaptations
The analysis of anabolic and catabolic hormonal
responses to training has been used as general indicators
of training status. For example, reductions in total and/or
free testosterone and/or excessive increases in cortisol dur-
ing training have been related to overtraining [42]. Fur-
thermore, analysis of the ratio of testosterone: cortisol has
been used as a general marker of anabolic: catabolic status
in trained athletes [42]. Theoretically, improving the ratio
of testosterone to cortisol may enhance the hormonal
environment for recovery and/or promote muscle hyper-
trophy during training. Results from the present study
indicate that AA supplementation did not significantly
affect resting levels of tTEST, fTEST, or CORT. These find-
ings indicate that AA had no effect on the anabolic and/or
catabolic status during training in experienced resistance-
trained individuals.
While AA supplementation appeared to not affect PGF2α
levels (P = 0.14), AA supplementation tended to increase
circulating levels PGE2 (AA: 98.5 ± 217 vs. PLA: -73.8 ±
273 pg·ml-1, P = 0.06). While not statistically significant,
this represented a 44% increase in PGE2 levels in the AA
group over the 50 d supplementation period compared to
a 25% decrease in the PLA group. These findings tend to
support contentions that AA supplementation may influ-
ence prostaglandin levels. The decrease in PGE2 in the PLA
group may be attributed to the restriction of AA contain-
ing foods in the diet. As mentioned previously, Kelly et al.
[19] demonstrated that supplementing young, healthy
men with AA increased the in vitro leukocytic secretion of
PGE2 upon stimulation with influenza microtiters. How-
ever, no previous study to our knowledge has demon-
strated that AA supplementation increases resting serum
levels of PGE2 and/or PGF2α. Additional research should
examine the acute and chronic effects of AA supplementa-
tion on PGE2 and PGF2α levels in relation to exercise and
inflammation.
Interleukin-6 is a cytokine that increases in response to
acute inflammation [42]. Intense exercise has been
reported to increase IL-6 secretion from the muscle by as
much as 100-fold in humans [43]. Consequently, IL-6 is
often used as an indicator of muscle inflammation status
in athletes. Past research also contends that IL-6 acts as a
pro-inflammatory cytokine thereby initiating intramuscu-
lar proteolytic activity by up-regulating lysosomal, cathe-
Table 3: Hormone/Cytokine Concentrations.
Variable AA (n = 15) PLA (n = 16) Significance
PGF2α (pg·ml-1)
Day 0 164.6 ± 104.4 183.6 ± 96.0 Group: 0.89
Day 25 221.5 ± 153.2 281.5 ± 248.2 Time: 0.06
Day 50 209.7 ± 226.3 150.0 ± 104.5 G × T: 0.14
PGE2 (pg·ml-1)
Day 0 224.3 ± 145.7 293.6 ± 256.7 Group: 0.97
Day 25 288.5 ± 191.2 314.8 ± 236.1 Time: 0.65
Day 50 322.8 ± 281.2 219.9 ± 163.6 G × T: 0.06
tTEST (ng·ml-1)
Day 0 21.4 ± 24.8 14.0 ± 12.1 Group: 0.25
Day 25 18.7 ± 22.4 12.2 ± 7.1 Time: 0.24
Day 50 18.7 ± 18.3 12.2 ± 7.7 G × T: 0.83
fTEST (pg·ml-1)
Day 0 25.3 ± 14.7 24.9 ± 19.6 Group: 0.82
Day 25 23.1 ± 12.1 20.0 ± 12.1 Time: 0.03
Day 50 22.3 ± 13.6 22.3 ± 15.0 G × T: 0.87
CORT (µg·dl-1)
Day 0 34.0 ± 24.1 26.2 ± 10.6 Group: 0.44
Day 25 28.2 ± 20.0 23.1 ± 7.8 Time: 0.06
Day 50 36.8 ± 22.9 34.2 ± 35.8 G × T: 0.57
IL-6 (pg·ml-1)
Day 0 137.2 ± 69.6 120.1 ± 92.1 Group: 0.63
Day 25 138.0 ± 83.1b 172.6 ± 90.5a Time: 0.001
Day 50 108.4 ± 48.6a 127.0 ± 56.8 G × T: 0.03
Values are expressed as means ± SD.
AA: Arachidonic acid, PLA: placebo, PGF2α: prostaglandin F2α, PGE2: prostaglandin E2, tTEST: total testosterone, fTEST: free testosterone, CORT: 
cortisol, IL-6: interleukin-6.
aSignificant within-group difference from baseline values, p < 0.05.
bSignificant group × time (G × T) interaction, p < 0.05.Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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psin, and ubiquitin pathways [44-48]. In fact, one of the
initial theories related to the potential ergogenic value of
AA for athletes was that dietary supplementation of AA
during training would promote greater localized inflam-
mation thereby stimulating subsequent intramuscular
protein synthesis during resting/repair phases between
workouts. Nonetheless, present findings do not support
this hypothesis. Rather, results suggest that AA supple-
mentation during training may reduce chronic levels of
IL-6 thereby reducing associated inflammation that may
occur during high volume training. Theoretically, this
may allow athletes to tolerate high levels of training to a
better degree. However, more research is needed to exam-
ine the acute and long-term effects that AA has on intra-
muscular muscle proteolysis following resistance training
before conclusions can be drawn.
Intramuscular adaptations
Prolonged resistance training has been reported to
increase the mRNA and protein expression of the MHC
type IIa isoform while decreasing type IIx and minimally
altering type I isoform expression patterns [43]. Further-
more, the aforementioned protein expression pattern of
these MHC isoforms in skeletal muscle has been highly
correlated with muscular hypertrophy [42]. Since AA has
been purported to promote muscle hypertrophy, we used
these markers to help determine whether AA influenced
cellular adaptations to training. Previous research has
shown that AA and PGF2α both up-regulate phosphoinosi-
tol-3 kinase (PI-3K)-p70S6k signaling in vascular smooth
muscle cells. This intracellular pathway in skeletal muscle
is known to initiate mRNA translation and is also highly
correlated with skeletal muscle hypertrophy [49-52].
Nonetheless, results of this study indicate that changes in
MHC protein expression were similar in both groups.
Therefore, AA supplementation during training had no
effect on MHC protein expression.
Myofibrillar protein content is also one of several markers
of muscle hypertrophy. Theoretically, if AA promoted
muscle hypertrophy, protein content of muscle fibers
would increase as has been previously shown in muscle
hypertrophy research. Yet, there was no evidence that AA
promoted increases in a number of markers of muscle
hypertrophy. In fact, myofibrillar protein levels were actu-
ally significantly increased in the PLA group while remain-
ing unchanged in the AA group. While past research
suggests that PGE2 induces lysosomal proteolysis in cul-
tured myotubes [53], it is currently not known if AA
mechanistically alters myofibrillar protein levels. Present
findings indicate that AA supplementation had no influ-
ence on muscle hypertrophy during training as indicated
by lack of effect on myofibrillar protein content, MHC
protein levels, and fat free mass.
The FP and EP3  receptors are ubiquitously expressed
throughout the body and exhibit pleiotropic metabolic
responses when stimulated. Of particular interest, cardio-
myocyte hypertrophy through activation of the ERK2
pathway has been shown to occur through the FP receptor
[49]. Similarly, EP3  receptor signaling mitigates decre-
ments in cyclic AMP production [54] which promotes the
signaling of the mammalian target of rapamycin (mTOR)
as well as subsequent assembly of the eukaryotic initia-
tion factor-4G (eIF-4G) [55]. Due to the fact that both of
these responses downstream from these receptors are inte-
gral to muscular hypertrophy, we chose to examine if AA
supplementation increased the expression of the FP and
EP3 receptors. Contrary to our initial hypothesis, however,
our findings reveal that AA did not affect chronic FP and/
or EP3  receptor densities. Regardless, future research
should examine if the abovementioned pathways are
acutely increased after exercise.
Conclusion
A potential limitation to this study was that the PLA group
ingested a corn oil supplement which is a source of lino-
leic acid substrate (22.9 mg·g oil-1) that can be converted
into arachidonic acid through a multi-catalytic process
involving the ∆6-desaturase, elongase, and ∆5-desaturase
enzymes, respectively [56]. However, it should be noted
that dietary analysis revealed no significant changes
between groups in linoleic acid intake throughout the
duration of the study. Another interesting finding was the
Delta changes in IL-6 levels over the 50 d supplement inter- vention Figure 2
Delta changes in IL-6 levels over the 50 d supplement inter-
vention. All values are expressed as means ± SD. ‡Signifi-
cantly different from baseline, p < 0.05. †Significant group × 
time interaction between AA and PLA groups, p < 0.05. AA: 
Arachidonic acid (n = 15); PLA: placebo (n = 16).Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
Page 11 of 13
(page number not for citation purposes)
significant reduction in IL-6 levels within the AA group at
day 25 and not day 50. While past research has examined
dietary-induced changes in intracellular fatty acid stores
and cytokine production via peripheral blood mononu-
clear cell stimulation in vitro [57], we measured IL-6 and
prostanoid levels in duplicate from serum samples. There-
fore, future research should be employed using analytical
techniques similar to Bell et al. [57] assessing the cellular
production of prostanoids and cytokines after ingesting
AA over prolonged periods. Beyond these potential limi-
tations, our results suggest that prolonged AA supplemen-
tation may increase cycling anaerobic capacity while
reducing circulating IL-6 levels in resistance-trained
males. Moreover, that 1.0 g·day-1 of AA administration
over a 50 days period significantly increased dietary AA
intake and appears to be well-tolerated and exerts no
adverse side effects in young, resistance-trained males.
These findings provide preliminary evidence that AA sup-
plementation may have some benefit for individuals
engaged in intense resistance-training. However, although
some potentially beneficial trends were observed, AA sup-
plementation had no statistically significant effects on
strength, muscle mass, hormonal markers of anabolism/
catabolism, or intracellular markers of muscle hypertro-
phy. Whether training status, dosage, supplement timing,
length of supplementation, sample size, and/or the type
of training may yield more positive results remains to be
examined with additional research. Additionally, whether
some athletes may respond better to AA supplementation
than others should be explored.
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Table 4: Intramuscular Adaptations and MHC mRNA Expression
Marker AA (n = 15) PLA (n = 16) Significance
Total protein (µg·g-1) Group: 0.92
Day 0 7.5 ± 4.5 6.6 ± 3.8 Time: 0.28
Day 50 7.0 ± 4.5 8.2 ± 4.3a,b G × T: 0.05
FP receptor (INT·mm2·mg-1) Group: 0.63
Day 0 1,929 ± 1,395 2,253 ± 1,309 Time: 0.13
Day 50 2,425 ± 1,746 2,518 ± 992 G × T: 0.64
EP3 receptor (INT·mm2·mg-1) Group: 0.55
Day 0 5,990 ± 3,563 6,854 ± 3,287 Time: 0.11
Day 50 7,149 ± 3,383 7,529 ± 2,791 G × T: 0.66
MHC I protein (ng·ml-1) Group: 0.78
Day 0 187.8 ± 180.7 172.8 ± 123.0 Time: 0.64
Day 50 176.3 ± 104.4 164.3 ± 126.6 G × T: 0.96
MHC IIa protein (ng·ml-1) Group: 0.84
Day 0 184.4 ± 217.1 156.9 ± 84.5 Time: 0.009
Day 50 305.0 ± 366.3 295.8 ± 328.5 G × T: 0.84
MHC IIx protein (ng·ml-1) Group: 0.55
Day 0 128.7 ± 79.1 133.6 ± 83.5 Time: 0.23
Day 50 103.9 ± 68.2 131.9 ± 81.7 G × T: 0.29
MHC I mRNA Group: 0.45
Day 0 0.69 ± 0.16 0.68 ± 0.14 Time: 0.70
Day 50 0.64 ± 0.07 0.71 ± 0.15 G × T: 0.14
MHC IIa mRNA Group: 0.32
Day 0 0.66 ± 0.12 0.66 ± 0.14 Time: 0.55
Day 50 0.63 ± 0.07 0.71 ± 0.13 G × T: 0.08
MHC IIx mRNA Group: 0.42
Day 0 0.66 ± 0.14 0.65 ± 0.15 Time: 0.98
Day 50 0.62 ± 0.07 0.69 ± 0.14 G × T: 0.10
Values are expressed as means ± SD.
AA: Arachidonic acid, PLA: placebo, INT: integrated density units, MHC: myosin heavy chain.
aSignificant within-group difference from baseline values, p < 0.05.
bSignificant group × time (G × T) interaction, p < 0.05Journal of the International Society of Sports Nutrition 2007, 4:21 http://www.jissn.com/content/4/1/21
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